These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38559621)

  • 1. Endotoxemia and Platelets: 2 Players of Intrahepatic Microthrombosis in NAFLD.
    Violi F; Pastori D; Pignatelli P; Cammisotto V
    JACC Basic Transl Sci; 2024 Mar; 9(3):404-413. PubMed ID: 38559621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut dysbiosis-derived low-grade endotoxemia: A common basis for liver and cardiovascular disease.
    Violi F; Nocella C; Bartimoccia S; Castellani V; Carnevale R; Pignatelli P; Cammisotto V
    Kardiol Pol; 2023; 81(6):563-571. PubMed ID: 37191190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut barrier dysfunction and endotoxemia in heart failure: A dangerous connubium?
    Violi F; Castellani V; Menichelli D; Pignatelli P; Pastori D
    Am Heart J; 2023 Oct; 264():40-48. PubMed ID: 37301317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
    Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
    Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis.
    Violi F; Pignatelli P; Castellani V; Carnevale R; Cammisotto V
    Blood Rev; 2023 Jan; 57():100998. PubMed ID: 35985881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets.
    Miele L; Alberelli MA; Martini M; Liguori A; Marrone G; Cocomazzi A; Vecchio FM; Landolfi R; Gasbarrini A; Grieco A; De Candia E
    Transl Res; 2021 May; 231():24-38. PubMed ID: 33171266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.
    Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
    World J Hepatol; 2015 Mar; 7(3):559-65. PubMed ID: 25848479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease.
    Fei N; Bruneau A; Zhang X; Wang R; Wang J; Rabot S; Gérard P; Zhao L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32019793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
    Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
    World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.
    An L; Wirth U; Koch D; Schirren M; Drefs M; Koliogiannis D; Nieß H; Andrassy J; Guba M; Bazhin AV; Werner J; Kühn F
    J Gastrointest Surg; 2022 Mar; 26(3):671-683. PubMed ID: 34734369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
    Silva-Veiga FM; Miranda CS; Vasques-Monteiro IML; Souza-Tavares H; Martins FF; Daleprane JB; Souza-Mello V
    World J Gastroenterol; 2022 May; 28(17):1814-1829. PubMed ID: 35633911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies.
    Papa A; Santini P; De Lucia SS; Maresca R; Porfidia A; Pignatelli P; Gasbarrini A; Violi F; Pola R
    Thromb Res; 2023 Dec; 232():77-88. PubMed ID: 37951044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
    Kessoku T; Kobayashi T; Tanaka K; Yamamoto A; Takahashi K; Iwaki M; Ozaki A; Kasai Y; Nogami A; Honda Y; Ogawa Y; Kato S; Imajo K; Higurashi T; Hosono K; Yoneda M; Usuda H; Wada K; Saito S; Nakajima A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
    Villard A; Boursier J; Andriantsitohaina R
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut Microbiota and Host Reaction in Liver Diseases.
    Fukui H
    Microorganisms; 2015 Oct; 3(4):759-91. PubMed ID: 27682116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease.
    Ciavarella A; Gnocchi D; Custodero C; Lenato GM; Fiore G; Sabbà C; Mazzocca A
    Thromb Res; 2021 Feb; 198():139-150. PubMed ID: 33340925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?
    Loffredo L; Zicari AM; Perri L; Carnevale R; Nocella C; Angelico F; Del Ben M; Mosca A; Zaffina S; Panera N; Alisi A; Duse M; Violi F; Nobili V
    Antioxid Redox Signal; 2019 Apr; 30(10):1325-1330. PubMed ID: 30019598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis.
    Han H; Jiang Y; Wang M; Melaku M; Liu L; Zhao Y; Everaert N; Yi B; Zhang H
    Crit Rev Food Sci Nutr; 2023; 63(12):1689-1706. PubMed ID: 34404276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.